

Review

Open Access



Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways

Chi Teng^{1,2,3,#}, Jia-Wen Chen^{1,2,3,#}, Li-Sha Shen⁴, Sibao Chen^{2,3,5,6} , Guo-Qing Chen^{1,3} 

¹College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, Guangdong, China.

²Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.

³State Key Laboratory of Chinese Medicine and Molecular Pharmacology (Incubation), The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen 518057, Guangdong, China.

⁴Chongqing Academy of Chinese Materia Medica, Chongqing 400065, China.

⁵Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong 999077, China.

⁶Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University, Hong Kong 999077, China.

#Authors contributed equally.

Correspondence to: Dr. Guo-Qing Chen, College of Pharmacy, Shenzhen Technology University. No. 3002, Lantian Road, Pingshan District, Shenzhen 518118, Guangdong, China. E-mail: chenguoqing@sztu.edu.cn

How to cite this article: Teng C, Chen JW, Shen LS, Chen S, Chen GQ. Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways. *Cancer Drug Resist.* 2025;8:13. <https://dx.doi.org/10.20517/cdr.2024.178>

Received: 9 Nov 2024 **First Decision:** 6 Jan 2025 **Revised:** 4 Mar 2025 **Accepted:** 10 Mar 2025 **Published:** 24 Mar 2025

Academic Editor: Godefridus J. Peters **Copy Editor:** Pei-Yun Wang **Production Editor:** Pei-Yun Wang

Abstract

Cancer remains a significant global health challenge, with current chemotherapeutic strategies frequently limited by the emergence of resistance. In this context, natural compounds with the potential to overcome resistance have garnered considerable attention. Among these, sesquiterpene lactones, primarily derived from plants in the Asteraceae family, stand out for their potential anticancer properties. This review specifically focuses on five key signaling pathways: PI3K/Akt/mTOR, NF- κ B, Wnt/ β -catenin, MAPK/ERK, and STAT3, which play central roles in the mechanisms of cancer resistance. For each of these pathways, we detail their involvement in both cancer development and the emergence of drug resistance. Additionally, we investigate how sesquiterpene lactones modulate these pathways to overcome resistance across diverse cancer types. These insights highlight the potential of sesquiterpene lactones to drive the advancement of novel therapies that can effectively combat both cancer progression and drug resistance.

Keywords: Sesquiterpene lactone, natural product, anticancer, drug resistance



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



INTRODUCTION

Cancer remains a major global public health threat, with significant impacts on human well-being. In 2018, the World Health Organization reported that cancer was the second leading cause of death worldwide, accounting for approximately 9.6 million deaths annually^[1]. Although significant progress has been made in treatment options, including chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy, the effectiveness of these approaches is often compromised by the emergence of chemotherapy resistance. This resistance reduces therapeutic efficacy and frequently results in treatment failure^[2]. Consequently, understanding and addressing the underlying mechanisms of drug resistance is crucial for advancing both experimental and clinical cancer research, highlighting the urgent need for novel anticancer agents.

Natural products derived from microorganisms, fungi, and plants have attracted significant attention as promising sources of innovative anticancer agents. These compounds are valued for their unique biological activities and chemical diversity. Notable examples such as vincristine, etoposide, topotecan, and paclitaxel have been successfully developed into clinically approved therapies^[3]. Their appeal lies not only in their potent anticancer effects but also in their relatively lower toxicity profiles and reduced likelihood of inducing drug resistance. Moreover, many natural products are capable of overcoming multidrug resistance (MDR), further highlighting their potential in modern cancer treatment^[4].

Among these natural products, sesquiterpene lactones, a prominent class of secondary metabolites derived primarily from plants of the Asteraceae family, stand out for their diverse biological activities^[5]. Characterized by a 15-carbon skeleton composed of three isoprene units and a γ -lactone group (cyclic ester), these compounds display remarkable structural diversity. This diversity underpins their antibacterial, anti-inflammatory, and anticancer properties, making them promising candidates for drug discovery^[6].

Emerging evidence underscores the significant anticancer potential of sesquiterpene lactones, particularly their effects on cancer cell development, proliferation, and metastasis^[7]. These compounds modulate key signaling pathways involved in cancer progression, including apoptosis induction, cell cycle arrest, and immune response regulation within the tumor microenvironment. Notably, compounds such as artemisinin, artesunate, and parthenolide have advanced to clinical trials, further demonstrating their therapeutic potential^[8-10]. In addition, sesquiterpene lactones have shown promise in overcoming drug resistance. For instance, xanthatin, costunolide, and micheliolide sensitize cancer cells to chemotherapeutic agents, providing innovative strategies to address this challenge^[11-13]. These findings highlight the dual role of sesquiterpene lactones as both potent anticancer agents and modulators of drug resistance, reinforcing the need for a comprehensive review of recent research progress.

This review systematically analyzes research articles published between 2014 and 2024, from Google Scholar and PubMed, focusing on the anticancer and resistance-modulating properties of sesquiterpene lactones. After rigorous screening, 30 compounds with significant anticancer activity and potential to overcome drug resistance were identified. We first classify these compounds and present their chemical structures, natural sources, and anticancer activities. We then explore their mechanisms, focusing on five critical signaling pathways: phosphoinositide 3-kinase (PI3K)/Akt/mTOR, nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), Wnt/ β -catenin, mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and signal transducer and activator of the transcription 3 (STAT3), which play pivotal roles in cancer progression and drug resistance. By elucidating these mechanisms, this review aims to offer valuable insights into the development of sesquiterpene lactones as therapeutic agents, advancing both basic and clinical research.

CLASSIFICATION OF SESQUITERPENE LACTONES WITH ANTICANCER ACTIVITY

Recent studies have identified several classes of sesquiterpene lactones with significant anticancer properties, derived from plants such as *Artemisia annua* L., *Inula helenium* L., *Elephantopus scaber* L., *Centipeda minima* L., and *Tanacetum parthenium* L. These compounds exhibit remarkable structural diversity, which correlates with their distinct biological activities, making them promising candidates for anticancer drug development^[10,14-17]. The following sections will examine the structural features and anticancer activities of key sesquiterpene lactone groups.

Artemisinin compounds

Sesquiterpene lactones derived from *Artemisia annua* L., collectively known as artemisinin and its derivatives, are shown in [Figure 1](#). Artemisinin (1), a sesquiterpene lactone featuring an endoperoxide moiety, gained global recognition for its potent antimalarial activity following its isolation in the 1970s by Chinese scientist Tu Youyou^[18]. Structurally, artemisinin is characterized by its unique peroxide bridge, lactone ring, and a rare 1,2,4-trioxane unit^[19], with the peroxide bond playing a crucial role in its pharmacological effects^[20]. The discovery of artemisinin revolutionized malaria treatment, establishing it as the first-line therapy. However, its clinical application is limited by challenges such as poor bioavailability, water solubility, and a short half-life^[21]. To overcome these limitations, derivatives with improved pharmacokinetic profiles have been developed. For example, artemisinin can be reduced to dihydroartemisinin (2) using sodium borohydride, which is then esterified with succinic anhydride to produce artesunate (3)^[22]. These derivatives exhibit improved chemical stability and water solubility, enhancing their clinical efficacy.

Beyond its well-established antimalarial effects, artemisinin compounds have gained attention for their significant anticancer potential^[23]. For example, Jia *et al.* demonstrated that artemisinin inhibits gallbladder cancer (GBC) cell proliferation by inducing apoptosis through increased intracellular reactive oxygen species (ROS)^[24]. Similarly, Li *et al.* showed that artemisinin and artesunate induce ROS-dependent DNA damage and inhibit metastasis in human non-small cell lung cancer (NSCLC) A549 cells^[25]. Clinical studies further highlight the anticancer potential of artemisinin derivatives, as artesunate has been shown to induce apoptosis in cancer cells via oxidative stress, significantly inhibiting tumor growth and improving survival in colorectal cancer (CRC) patients during Phase I trials^[8]. Additionally, artemisinin compounds have demonstrated inhibitory effects on other malignancies, including bladder cancer (BCa), embryonal rhabdomyosarcoma (ERMS), epithelial ovarian cancer (EOC), and diffuse large B-cell lymphoma (DLBCL)^[26-30].

Alantolactone compounds

Alantolactone compounds, shown in [Figure 2](#), include alantolactone (4), isoalantolactone (5), costunolide (6), and dehydrocostus lactone (7). These sesquiterpene lactones are primarily derived from the medicinal plant *Inula helenium* L. (Asteraceae), which is known for its diverse bioactive constituents, including sesquiterpene lactones, flavonoids, amino acids, triterpenes, alkaloids, and phytosterols^[31-33]. Among these, sesquiterpene lactones are particularly notable for their therapeutic potential. Contemporary pharmacological research has highlighted a range of biological activities for alantolactone compounds, including anticancer, anti-inflammatory, anthelmintic, antibacterial, hypoglycemic, and analgesic effects^[34].

Structurally, alantolactone, isoalantolactone, and dehydrocostus lactone belong to the tricyclic sesquiterpene lactone class, while costunolide features two unsaturated ring structures. Despite sharing the same molecular formula, these compounds exhibit distinct chemical arrangements that result in varied pharmacodynamics and therapeutic effects. Notably, these compounds are not exclusive to *Inula helenium*




Figure 1. The chemical structures of artemisinin compounds. (1) Artemisinin; (2) Dihydroartemisinin; (3) Artesunate.




Figure 2. The chemical structures of alantolactone compounds. (4) Alantolactone; (5) Isoalantolactone; (6) Costunolide; (7) Dehydrocostus lactone.

L.; related species, such as *Aucklandia lappa* Decne, also contain similar bioactive sesquiterpene lactones^[35].

Recent studies have underscored the anticancer potential of alantolactone compounds. For example, Chen *et al.* reported that alantolactone suppresses the growth of esophageal adenocarcinoma (EAC) KYAE-1 cells by inducing apoptosis via inhibition of the nuclear factor E2-related factor 2 (Nrf2) pathway^[36]. Similarly, Ren *et al.* found that alantolactone induces apoptosis in CRC HCT116 cells, effectively suppressing tumor growth^[37]. Additionally, Yin *et al.* demonstrated the growth-inhibitory properties of alantolactone in triple-negative breast cancer (TNBC) MDA-MB-231 cells^[38].

Beyond alantolactone, other structurally related compounds also exhibit potent anticancer activity. Isoalantolactone, for instance, has shown significant inhibitory effects against malignant tumors such as hepatocellular carcinoma (HCC), CRC, and pancreatic cancer^[39-41]. Costunolide has also been reported to induce apoptosis in CRC, gastric cancer (GC), and skin cancer cells^[42-44]. Among these, dehydrocostus lactone has garnered increasing attention for its potent anticancer effects. For instance, Peng *et al.* demonstrated that dehydrocostus lactone suppresses the proliferation of EAC Eca109 cells by inducing autophagy, both *in vitro* and *in vivo*^[45].

Deoxyelephantopin compounds

Deoxyelephantopin compounds, shown in Figure 3, form a subclass of sesquiterpene lactones derived from *Elephantopus scaber* L. These include deoxyelephantopin (8), isodeoxyelephantopin (9), scabertopin (10), elephantopinolide A (11), elephantopinolide F (12), elephantopinolide J (13), and the synthesized derivative




Figure 3. The chemical structures of deoxyelephantopin compounds. (8) Deoxyelephantopin; (9) Isodeoxyelephantopin; (10) Scabertopin; (11) Elephantopinolide A; (12) Elephantopinolide F; (13) Elephantopinolide J; and (14) DETD-35.

DETD-35 (14). The discovery of deoxyelephantopin compounds dates back to the 1970s when Wolo *et al.* first isolated deoxyelephantopin from *Elephantopus* species^[46]. Shortly thereafter, isodeoxyelephantopin, an isomer of deoxyelephantopin, was identified in the same species^[47]. Further research leads to the identification of additional sesquiterpene lactones, including scabertopin, elephantopinolide A, elephantopinolide F, and elephantopinolide J^[48].

The anticancer efficacy of deoxyelephantopin compounds has been extensively studied, with several demonstrating broad-spectrum anticancer effects. For example, deoxyelephantopin itself has shown promising activity against various cancers. Kabeer *et al.* reported its efficacy against oral epidermoid cancer (KB), CRC (HCT116), and leukemia (K562) cell lines^[49]. Similarly, its isomer, isodeoxyelephantopin, has also exhibited notable anticancer potential. Hong *et al.* found that it induces apoptosis in CRC HCT116 and RKO cells^[50]. Building on these findings, Verma *et al.* further elucidated the mechanisms underlying isodeoxyelephantopin's anticancer effects. They demonstrated that the compound induces G2/M phase cell cycle arrest, triggers apoptosis, and inhibits metastasis in TNBC MDA-MB-231 cells^[51].

In addition to deoxyelephantopin and isodeoxyelephantopin, other compounds derived from *Elephantopus scaber* L. have also shown significant anticancer activity. For instance, scabertopin has demonstrated strong anticancer effects. Gao *et al.* found that it increases ROS levels in BCa J82 and T24 cells, inducing necroptosis^[17]. To enhance the anticancer capabilities of deoxyelephantopin compounds, researchers have explored structural modifications, leading to the synthesis of novel derivatives. One such derivative, DETD-35 (14), has shown promising results. Feng *et al.* synthesized DETD-35, which exhibits enhanced anticancer activity compared to its parent compounds^[52]. Nakagawa-Goto *et al.* demonstrated that DETD-35 significantly inhibits the invasion and migration of TNBC MDA-MB-231 cells^[53]. Furthermore, DETD-35 has been shown to induce apoptosis in melanoma A375 cells, cause G2/M phase cell cycle arrest, inhibit cell

migration, and enhance the sensitivity of A375 cells to the BRAF inhibitor vemurafenib^[52,54].

Beyond deoxyelephantopin derivatives, other sesquiterpene lactones from *Elephantopus scaber* L. have also displayed promising anticancer effects. For example, research on elephantopinolide A and elephantopinolide F revealed their ability to induce apoptosis in glioma U87 cells, as demonstrated by Yan *et al.*^[55]. Similarly, Bai *et al.* explored the effects of elephantopinolide J, showing that it induces G2/M phase cell cycle arrest, triggers autophagy, and promotes apoptosis in HCC HepG2 and Hep3B cells^[48].

Parthenolide compounds

Parthenolide compounds, a class of sesquiterpene lactones primarily from *Tanacetum parthenium* L., have garnered significant attention due to their anticancer properties. This group, shown in [Figure 4](#), includes parthenolide (15), dimethylaminoparthenolide (16), micheliolide (17), epoxymicheliolide (18), and dimethylaminomicheliolide (19).

Parthenolide, the foundational compound in this group, was initially isolated from *Tanacetum parthenium* L. and has also been found in other plant species within the Asteraceae and Magnoliaceae families. Its anticancer potential was first reported in the 1970s by Wiedhopf *et al.*, sparking widespread interest in its therapeutic applications^[56]. However, despite its promising properties, the clinical use of parthenolide has been hindered by several challenges, including high lipophilicity, poor water solubility, and limited bioavailability^[57]. To address these limitations, extensive research has focused on strategies to improve its pharmacokinetic profile. One effective approach has been structural modification. For example, modifying the α -methylene- γ -butyrolactone moiety via Michael addition has significantly improved water solubility while maintaining or enhancing its biological activity^[58]. This modification led to the development of dimethylaminoparthenolide, an amino derivative with superior solubility and bioavailability compared to the parent compound^[59]. In addition to solubility challenges, parthenolide demonstrates chemical instability under acidic and alkaline conditions, further limiting its clinical utility. To overcome this, more stable derivatives, such as micheliolide and epoxymicheliolide, have been developed. Micheliolide exhibits greater chemical stability, making it more suitable for therapeutic applications^[60]. Its anticancer mechanism is thought to rely on its α -methylene- γ -lactone structure, which is crucial for its activity^[61,62]. Dimethylaminomicheliolide, a Michael adduct of micheliolide, has further enhanced stability, increased anticancer activity, and shown lower toxicity compared to micheliolide itself^[63,64].

Extensive research has explored the anticancer activities of these sesquiterpene lactones across various cancer types. Parthenolide, for example, has demonstrated efficacy in inducing G1/G0 phase cell cycle arrest and apoptosis in several cancers. Karam *et al.* reported its ability to suppress primary effusion lymphoma (PEL) BC3 and BC1 cells, while dimethylaminoparthenolide extended the survival of NOD/SCID mice^[65]. Similarly, Li *et al.* showed that parthenolide halts the progression of GC SGC-7901 cells in the G0/G1 phase, induces apoptosis, and inhibits cell migration and invasion, even overcoming cisplatin resistance^[66]. Furthermore, parthenolide triggers apoptosis in NSCLC A549 and H1299 cells and significantly suppresses tumor growth in an A549 xenograft mouse model^[67]. Additional studies have confirmed its apoptosis-inducing effects in pancreatic and cervical cancer models^[68,69].

Micheliolide has also shown notable anticancer effects, inducing apoptosis in GC^[70], glioma^[71], and liver cancer cells^[13], among others. Moreover, Zhu *et al.* demonstrated that epoxymicheliolide causes G1/G0 cell cycle arrest, triggers apoptosis, and impedes metastasis in renal cell carcinoma (RCC) 786-0 and Caki-1 cells^[62].




Figure 4. The chemical structures of parthenolide compounds. (15) Parthenolide; (16) Dimethylaminoparthenolide; (17) Micheliolide; (18) Epoxymicheliolide; (19) Dimethylaminomicheliolide.

Dimethylaminomicheliolide, a key derivative of micheliolide, has exhibited remarkable anticancer properties. Zhang *et al.* reported its ability to induce apoptosis and inhibit cellular aerobic glycolysis in neuroblastoma NGP and BE2 cells, highlighting its impact on cancer metabolic reprogramming^[72]. Additionally, studies by Yao *et al.* and Wang *et al.* revealed that dimethylaminomicheliolide effectively suppresses the migration and invasion of liver cancer cells and induces autophagy and apoptosis in glioma cells^[73,74].

Sesquiterpene lactones derived from *Centipeda minima*

In recent years, several sesquiterpene lactones have been identified in *Centipeda minima* L., with arnicolide D (20) and brevilin A (21) emerging as the most prominent compounds for their anticancer activity, as shown in Figure 5. The structural configuration of these compounds is notably distinct from those derived from other plant species, particularly due to the presence of an α,β -unsaturated lactone moiety within the A ring. This moiety functions as a Michael acceptor, significantly enhancing their biological activity^[75]. Furthermore, the C/B ring junction at positions 7 and 8, along with diverse substitutions at position 6 (e.g., angeloyl, methacryloyl, and methylcrotonyl groups), highlights their potential specificity in biological interactions^[76]. These unique chemical features establish arnicolide D and brevilin A as promising candidates for the development of innovative anticancer agents.

Our recent studies have highlighted the potent anticancer effects of arnicolide D across various cancers. Arnicolide D consistently induces apoptosis and G2/M phase cell cycle arrest, as observed in nasopharyngeal carcinoma (NPC) CNE-2 cells^[77], TNBC MDA-MB-231 cells^[78], and melanoma B16F10 cells^[79]. Additionally, our latest research revealed that arnicolide D induces oncosis in HCC cells through ER stress mediated by CHOP and ATF4 pathways^[80]. Other studies have further demonstrated arnicolide D's ability to suppress proliferation and induce apoptosis in osteosarcoma (OS) cells^[81].




Figure 5. The chemical structures of sesquiterpene lactones derived from *Centipeda minima*. (20) Arnicolide D; (21) Brevilin A.

Beyond arnicolide D, our group has also explored the anticancer activity of brevilin A in various cancer models. Brevilin A demonstrates strong anti-melanoma effects by inducing apoptosis and inhibiting metastasis *in vitro*, as well as significantly suppressing tumor growth in a xenograft A375 mouse model^[82]. It also induces G2/M phase arrest and apoptosis in NPC CNE-2 cells, further supporting its potential against NPC^[83]. Additionally, Saleem *et al.* reported that brevilin A triggers apoptosis and ER stress while inducing G2/M phase cell cycle arrest. Furthermore, brevilin A has been shown to inhibit the migration and invasion of MCF-7 breast cancer cells^[84]. You *et al.* also demonstrated that brevilin A promotes both apoptosis and autophagy in CRC CT26 cells, underscoring its broad-spectrum anticancer efficacy^[85].

Sesquiterpene lactones from other sources

Recent studies have identified numerous natural sesquiterpene lactones with significant anticancer activity from various plant sources, as shown in Figure 6. Among these, britannin (22), a sesquiterpene lactone originally derived from *Inula aucheriana* Thunb. of the Asteraceae family, has demonstrated notable anticancer properties in various cancer models^[86]. Beyond its initial identification, britannin has also been extracted from other *Inula* species, including *Inula japonica* and *Inula linearifolia* Turcz^[87]. Studies have revealed that britannin inhibits both proliferation and angiogenesis in CRC HCT116 cells, highlighting its potential as an anticancer strategy^[88]. In HCC models, britannin triggers apoptosis through both extrinsic and intrinsic pathways and promotes autophagy, effectively suppressing cancer initiation and progression^[27].

Two additional sesquiterpene lactones, atractylenolide I (23) and atractylenolide II (24), have been isolated from *Atractylodes macrocephala* Koidz., and exhibit potent anticancer activities across multiple cancer cell lines^[89]. Atractylenolide I induces apoptosis and significantly hinders invasiveness in CRC COLO205 and HCT116 cells. In an *in vivo* mouse xenograft model on CRC, atractylenolide I effectively inhibits tumor growth^[90]. Meanwhile, atractylenolide II induces apoptosis and G2/M phase cell cycle arrest in human prostate cancer (PCa) cells (DU145 and LNCaP), thereby suppressing cell proliferation^[91].

Hemisteptin A (25), derived from *Hemistepta lyrata* Bunge, represents another promising sesquiterpene lactone for cancer therapy^[92]. It exerts potent anticancer effects in malignancies such as PCa and HCC by inducing autophagy and apoptosis, as well as inhibiting cell cycle progression^[15,93].




Figure 6. The chemical structures of sesquiterpene lactones from other sources. (22) Britannin; (23) Atractylenolide I; (24) Atractylenolide II; (25) Hemisteptsin A; (26) Xanthatin; (27) Tagitinin C; (28) Thapsigargin; (29) Antrocin; (30) Gaillardin.

Another group of sesquiterpene lactones can be extracted from *Xanthium strumarium* L.^[94]. Among these, xanthatin (26), a bicyclic sesquiterpene lactone, features a highly reactive α -methylene- γ -butenolide moiety critical for its pharmacological effects^[95]. Shi *et al.* demonstrated that xanthatin inhibits the viability of HCC cells (SMMC-7721, Bel-7402, and HepG2) by inducing G2/M phase arrest, apoptosis, and ER stress^[96].

Tagitinin C (27), initially extracted from *Tithonia diversifolia* A. Gray, is another notable sesquiterpene lactone with potent anticancer activity^[97]. Research conducted by Wei *et al.* revealed that tagitinin C induces ER stress, ferroptosis, and G2/M cell cycle arrest in CRC HCT116 cells, contributing to its anticancer properties^[98].

Thapsigargin (28), derived from *Thapsia garganica* L., stands out due to its unique trans-C7 α -C6 β - γ lactone ring configuration, which includes trans-hydroxyl groups at positions C7 and C11^[99]. This structural uniqueness underpins its potent biological activity. Huang *et al.* demonstrated that thapsigargin induces apoptosis and inhibits proliferation in PCa PC3 cells^[100]. Additionally, Wu *et al.* showed that thapsigargin induces ER stress and apoptosis in adrenocortical carcinoma (ACC) SW-13 cells, while suppressing cell migration and invasion^[101].

Antrocin (29), a cyclic sesquiterpene lactone first isolated from the fungus *Antrodia cinnamomea* by Chiang *et al.* in 1995, has shown significant potential as a novel anticancer agent^[102]. Chen *et al.* reported that antrocin markedly reduces tumorigenicity and stemness in TNBC both *in vitro* and *in vivo*^[102]. Furthermore, Chiu *et al.* found that antrocin induces apoptosis and reduces metastasis in BCa 5637 cells, underscoring its therapeutic potential for aggressive cancers^[103].

Gaillardin (30), a pseudoguaianolide-type sesquiterpene lactone derived from *Inula oculus-christi*, another Asteraceae species, has also garnered attention for its anticancer properties^[104]. Roozbehani *et al.* discovered that gaillardin impedes the proliferation of GC cells (AGS and MKN45) by inducing apoptosis^[104].

SIGNAL PATHWAYS INVOLVED IN THE CANCER DRUG RESISTANCE-OVERCOMING EFFECT OF SESQUITERPENE LACTONES

Signal transduction pathways are crucial in cancer progression, regulating key cellular processes like proliferation, survival, and drug resistance. This section focuses on five major pathways involved in cancer progression and drug resistance, specifically examining how sesquiterpene lactones modulate these pathways to enhance anticancer effects and overcome resistance mechanisms.

PI3K/Akt/mTOR pathway

The PI3K/serine-threonine protein kinase Akt (also known as protein kinase B, PKB)/mammalian target of rapamycin (mTOR) pathway, shown in [Figure 7](#), is critical for regulating various aspects of cancer biology, such as cell survival, growth, metabolism, and drug resistance^[105,106]. Dysregulation of this pathway, often initiated by cell surface receptors such as receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs), is a hallmark of many cancers and a major contributor to therapeutic resistance, making it a key target for intervention. PI3K is a family of lipid kinases, classified into three classes, with Class I being the most strongly implicated in tumorigenesis through the generation of phosphatidylinositol 3,4,5-triphosphate (PIP3)^[107]. The accumulation of PIP3 facilitates the membrane translocation of phosphoinositide-dependent kinase-1 (PDK1) and Akt^[108,109], leading to the phosphorylation of Akt at threonine 308 and serine 473, thereby activating downstream signaling pathways, including mTOR^[110]. mTOR exists in two distinct complexes: mTORC1, which regulates cellular growth, protein synthesis, and cell cycle progression, and mTORC2, which primarily governs cytoskeletal organization and cell survival^[111,112].

This pathway is not only for cancer cell proliferation but also plays a crucial role in developing resistance to various chemotherapeutic agents. Increased expression and activation of PI3K and Akt in multiple tumor types lead to enhanced mTOR activity, which promotes tumor initiation, progression, and metastasis^[113]. This pathway contributes to drug resistance by inhibiting apoptotic signaling and promoting cell survival under stress conditions, thus complicating treatment efficacy^[114]. Studies have shown that sesquiterpene lactones like antrocin and artesunate target key components of this pathway. These compounds inhibit PI3K and Akt activation, downregulate mTOR signaling, and reverse drug resistance in HCC cells, improving therapeutic outcomes^[115,116]. Additionally, artemisinin has been shown to enhance cancer cell sensitivity to 5-fluorouracil (5-FU) by inhibiting Akt phosphorylation, further supporting the potential of sesquiterpene lactones in overcoming drug resistance^[117].

The PI3K/Akt/mTOR pathway is also crucial in MDR, a significant challenge in cancer therapy^[118,119]. Activation of this pathway upregulates the expression and activity of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), which expels chemotherapeutic agents from the cytoplasm, lowering intracellular drug concentrations and contributing to MDR^[120]. Sesquiterpene lactones can reverse




Figure 7. An overview of the PI3K/Akt/mTOR pathway and its role in overcoming drug resistance mediated by sesquiterpene lactones. This pathway is activated by cell surface receptors, including RTKs and GPCRs, leading to PI3K activation and the generation of PIP3. PIP3 facilitates the phosphorylation of Akt and promotes the membrane translocation of both Akt and PDK1, triggering downstream signaling through mTOR. This activation enhances drug resistance by upregulating ABC transporter expression, thereby increasing drug efflux. Moreover, the PI3K/Akt/mTOR pathway regulates key processes such as autophagy and tumor proliferation through mTOR modulation. Its interaction with the TRAIL pathway further amplifies the complexity of drug resistance networks by influencing apoptosis, reinforcing the role of this pathway in resistance mechanisms. PI3K: Phosphoinositide 3-kinase; RTKs: receptor tyrosine kinases; GPCRs: G protein-coupled receptors; PIP3: phosphatidylinositol 3,4,5-triphosphate; PDK1: phosphoinositide-dependent kinase-1; ABC: ATP-binding cassette; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand.

MDR by downregulating P-gp expression and restoring chemotherapeutic efficacy. For example, costunolide enhances the sensitivity of K562/ADR chronic myeloid leukemia (CML) cells to doxorubicin through P-gp downregulation^[121]. Similarly, artemisinin increases the sensitivity of cisplatin-resistant GC cells (SGC7901/DDP) to cisplatin by inhibiting P-gp activity^[122].

Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is also often mediated by the PI3K/Akt/mTOR pathway^[123]. TRAIL, a member of the tumor necrosis factor (TNF) family, induces apoptosis by binding to its receptors, yet many cancer cells exhibit resistance to TRAIL-induced cell death, which limits its therapeutic potential^[124]. The pathway modulates TRAIL-induced apoptosis by phosphorylating and activating downstream signaling molecules and regulating TRAIL receptor expression, which diminishes TRAIL's effectiveness. Inhibiting the PI3K/Akt pathway enhances TRAIL-induced apoptosis by restoring receptor expression and promoting apoptosis in cancer cells. For instance, artesunate has been demonstrated to enhance TRAIL-induced apoptosis in human cervical cancer cells, overcoming TRAIL resistance^[125]. These findings suggest that sesquiterpene lactones, by targeting critical nodes in the

PI3K/Akt/mTOR pathway, hold promise as strategies for enhancing chemotherapy efficacy and overcoming drug resistance in various cancers.

NF- κ B pathway

The NF- κ B pathway plays a crucial role in regulating inflammation, immune response, and cancer development^[126,127]. As shown in [Figure 8](#), this pathway consists of five key members: RelA (p65), RelB, and c-Rel, NF- κ B1 (p50), NF- κ B2 (p52). In quiescent cells, NF- κ B proteins are sequestered in the cytoplasm by inhibitors from the I κ B family, which prevent their activation^[128]. The NF- κ B pathway is activated through two distinct signaling routes: the canonical (classical) pathway and the non-canonical (alternative) pathway.

The canonical NF- κ B pathway is characterized by rapid, transient activation in response to pro-inflammatory cytokines, microbial components, and stress signals. It is primarily initiated by key receptors such as interleukin-1 receptors (IL-1Rs), Toll-like receptors (TLRs), T-cell receptors (TCRs), and tumor necrosis factor receptors (TNFRs). Upon activation, I κ B kinases (IKKs) are phosphorylated, leading to the ubiquitin-dependent degradation of I κ B proteins. This degradation liberates NF- κ B dimers (typically p50/p65), allowing their translocation into the nucleus to regulate the expression of target genes^[129]. In contrast, the non-canonical NF- κ B pathway features slower and more sustained activation. It is primarily activated by specific members of the TNF receptor superfamily, such as BAFFR, CD40, and LT β R. Activation of NF- κ B-inducing kinase (NIK) results in the phosphorylation of IKK α , which subsequently phosphorylates p100. This phosphorylation leads to the partial degradation of p100 to p52. The p52/RelB complex then translocates to the nucleus, where it regulates genes involved in immune modulation and tumor progression^[130].

Dysregulated activation of the canonical NF- κ B pathway is implicated in several pathological conditions, including tumorigenesis and the development of drug resistance. Abnormal upstream signaling, excessive phosphorylation or degradation of I κ B proteins, and persistent or overactive IKK complex expression can result in sustained NF- κ B activation. This prolonged activation promotes tumor initiation, progression, and resistance to therapy^[131]. Sesquiterpene lactones exert their antitumor effects by inhibiting IKK activity, blocking I κ B phosphorylation and degradation, and preventing the NF- κ B/p65 dimer from translocating into the nucleus. As a result, NF- κ B nuclear accumulation is reduced, and its transcriptional activity is diminished, enhancing tumor cell sensitivity to chemotherapy. For instance, alantolactone inhibits TNF- α -induced I κ B α phosphorylation and blocks NF- κ B/p65 nuclear translocation, inducing apoptosis in imatinib-resistant CML cells and overcoming their resistance to imatinib^[132]. Similarly, parthenolide enhances sensitivity to oxaliplatin by suppressing NF- κ B/p65 signaling in lung cancer cells, mitigating oxaliplatin resistance^[133]. Resistance to gemcitabine, a standard chemotherapy for pancreatic cancer, is closely associated with aberrant NF- κ B activation^[134]. Studies show that both deoxyelephantopin and dimethylaminoparthenolide, when combined with gemcitabine, reverse resistance in pancreatic cancer cells by inhibiting NF- κ B/p65 signaling. This combined treatment approach significantly enhances gemcitabine's therapeutic efficacy in clinical settings^[135,136].

The NF- κ B pathway is also a key driver of MDR. Upon activation, the NF- κ B/p65 dimer translocates to the nucleus and upregulates the expression of the gene encoding P-gp. P-gp is involved in actively expelling chemotherapeutic agents from cancer cells, reducing intracellular drug concentrations and diminishing therapeutic efficacy^[137]. By inhibiting the NF- κ B pathway, sesquiterpene lactones have been shown to enhance chemosensitivity by downregulating P-gp expression. For example, dihydroartemisinin improves the sensitivity of HCC cells to doxorubicin via this mechanism^[138].




Figure 8. An overview of the canonical and non-canonical NF-κB pathways and their roles in regulating drug resistance in sesquiterpene lactones. The canonical NF-κB pathway is activated by pro-inflammatory cytokines and stress signals, which trigger the phosphorylation of IKKs. This phosphorylation leads to the degradation of IκB proteins, releasing NF-κB dimers, such as p50/p65. These dimers then translocate to the nucleus, where they regulate the expression of genes involved in inflammation, immune response, and tumor progression. In contrast, the non-canonical NF-κB pathway is activated by specific members of the TNF receptor superfamily, such as BAFFR, CD40, and LTβR. This activation leads to the activation of NIK, which in turn activates IKKα. IKKα phosphorylates p100, resulting in its partial degradation to generate p52. The p52/RelB complex then translocates to the nucleus, where it regulates genes associated with immunity and tumorigenesis. Activation of the canonical NF-κB pathway promotes the upregulation of P-gp, which enhances drug efflux and contributes to drug resistance. Additionally, NF-κB activation increases the expression of anti-apoptotic proteins such as FLIP, c-IAPs, TNFRs, and Bcl-2. These proteins inhibit apoptosis, thereby promoting chemotherapy resistance. NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; IKKs: IκB kinases; TNF: tumor necrosis factor; NIK: NF-κB-inducing kinase; P-gp: P-glycoprotein; FLIP: FLICE-inhibitory protein; TNFRs: tumor necrosis factor receptors.

In addition to facilitating drug efflux, NF-κB activation contributes to resistance by upregulating various anti-apoptotic proteins, such as FLICE-inhibitory protein (FLIP), c-IAPs, TNFRs, and Bcl-2^[139]. These proteins enhance tumor cell survival and confer resistance to chemotherapy-induced apoptosis, thereby contributing to drug resistance^[140,141]. Sesquiterpene lactones can inhibit NF-κB activity, leading to significant downregulation of these anti-apoptotic proteins and promoting tumor cell apoptosis. For example, dihydroartemisinin has been shown to overcome gemcitabine resistance in pancreatic cancer cells both *in vitro* and *in vivo*, enhancing therapeutic efficacy^[138]. These findings highlight the potential of sesquiterpene lactones in inhibiting NF-κB signaling, overcoming chemotherapy resistance, and improving treatment outcomes.

Wnt/ β -catenin pathway

The Wnt signaling pathway regulates a wide range of cellular processes, including tumor cell growth, differentiation, apoptosis, and autophagy. This pathway plays a critical role in tumorigenesis and has become an important target for therapeutic interventions^[142]. Conserved throughout evolution, the Wnt/ β -catenin pathway is essential for numerous physiological functions^[143], and its dysregulation is associated with the initiation and progression of various malignancies^[82,144,145].

As shown in [Figure 9](#), β -catenin is a central mediator in this signaling cascade, acting both as a cell adhesion protein and as a key effector in Wnt signaling^[146]. The pathway is initiated when Wnt ligands bind to a receptor complex on the cellular membrane, consisting of low-density lipoprotein receptor-related protein 5/6 (LRP-5/6) and Frizzled (FZD). In the absence of Wnt ligands, β -catenin is ubiquitinated and degraded by a destruction complex, which includes Axin, adenomatous polyposis coli (APC), and glycogen synthase kinase 3 beta (GSK3 β). Upon Wnt ligand binding, the destruction complex is inhibited, leading to the accumulation and nuclear translocation of β -catenin. In the nucleus, β -catenin interacts with T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) transcription factors and co-activators such as Pygopus and Bcl-9, activating target gene transcription^[147]. In addition to these roles, β -catenin also intersects with autophagy pathways, either by activating the PI3K/Akt/mTOR pathway or promoting the fusion of autophagosomes with lysosomes^[101,111,148,149].

While the Wnt/ β -catenin is crucial for embryonic development and tissue homeostasis, its aberrant activation is commonly observed in many cancers, making it a prime target for anticancer therapies. Notably, this pathway is also involved in cancer drug resistance. Under normal conditions, Wnt/ β -catenin signaling is tightly regulated through β -catenin stability. However, in various malignancies, abnormal accumulation of β -catenin leads to persistent activation of Wnt/ β -catenin signaling, driving tumor progression and contributing to drug resistance^[150-152].

Regulating β -catenin expression is therefore critical for how sesquiterpene lactones modulate Wnt/ β -catenin signaling to combat drug resistance. In glioblastoma, the chemotherapeutic agent temozolomide (TMZ), a DNA methylator, faces resistance due to Wnt/ β -catenin activation. This pathway enhances the expression of MGMT (O6-methylguanine-DNA-methyltransferase), contributing to TMZ resistance. Artesunate counteracts this by downregulating β -catenin expression, inhibiting Wnt/ β -catenin activation, and suppressing MGMT, thereby reversing TMZ resistance^[153]. Similarly, in EC, Wnt/ β -catenin signaling plays a critical role in drug resistance. Overactivation of β -catenin promotes cell survival and proliferation, reducing the effectiveness of oxaliplatin. Artemisinin enhances the sensitivity of EC cells to oxaliplatin by inhibiting Wnt/ β -catenin signaling^[154].

One effective strategy to reduce β -catenin levels is to enhance its degradation. GSK-3 β , a negative regulator of the Wnt/ β -catenin pathway, phosphorylates β -catenin, leading to its degradation^[155]. Sesquiterpene lactones activate GSK-3 β , promoting β -catenin phosphorylation and degradation. This inhibits Wnt/ β -catenin signaling and mitigates drug resistance. For example, dihydroartemisinin targets GSK-3 β to suppress Wnt/ β -catenin signaling in colon cancer, inhibiting tumor progression and overcoming resistance to capecitabine^[156].

In the Wnt/ β -catenin pathway, β -catenin binds to transcription factors such as TCF/LEF to activate downstream gene expression. Reducing β -catenin expression limits its interaction with these factors, disrupting the pathway's support of cell proliferation and drug resistance^[157]. Sesquiterpene lactones can indirectly inhibit these transcription factors by reducing β -catenin accumulation in the nucleus, enhancing




Figure 9. An overview of the Wnt/β-catenin pathway and its critical role in mediating drug resistance of sesquiterpene lactones in cancer cells. The pathway is activated when Wnt ligands bind to the FZD and LRP-5/6 receptor complex on the cell surface, triggering downstream signaling events. In the absence of Wnt ligands, β-catenin is ubiquitinated and degraded by a destruction complex consisting of Axin, APC, and GSK3β. However, when the Wnt pathway is activated, this destruction complex is inhibited, preventing β-catenin degradation. Consequently, β-catenin accumulates in the cytoplasm and translocates to the nucleus, where it activates the transcription of target genes. By activating β-catenin, the Wnt pathway enhances drug resistance through the upregulation of genes such as c-MYC, survivin, and MMP9, which play crucial roles in promoting cell proliferation. Sesquiterpene lactones counteract drug resistance by modulating β-catenin, GSK-3β, and the expression of downstream genes. FZD: Frizzled; LRP-5/6: lipoprotein receptor-related protein 5/6; APC: adenomatous polyposis coli; GSK3β: glycogen synthase kinase 3 beta.

chemotherapy sensitivity. For instance, dihydroartemisinin targets the Wnt/β-catenin/TCF7/MMP9 pathway, synergizing with capecitabine to enhance anticancer effects and overcome drug resistance in CRC^[156]. In EC, upregulation of Wnt/β-catenin target genes, such as c-Myc and survivin, promotes tumor progression and resistance. Artemisinin significantly reduces c-Myc and survivin expression, induces apoptosis, and reverses oxaliplatin resistance by inhibiting Wnt/β-catenin signaling^[154]. Thus, sesquiterpene lactones offer promising therapeutic strategies by inhibiting the overactivation of the Wnt/β-catenin pathway, demonstrating potent anti-resistance effects.

MAPK/ERK pathway

The MAPK/ERK pathway is a crucial signaling cascade that regulates key cellular processes, including proliferation, differentiation, apoptosis, and inflammatory responses^[158,159]. As shown in Figure 10, this pathway involves three primary classes of kinases: MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK/MEK), and MAPK, which sequentially phosphorylate downstream targets, thereby propagating the signal^[160]. In the canonical MAPK/ERK pathway, MAPKKKs, such as A-RAF, B-RAF, and RAF-1 (C-




Figure 10. An overview of the MAPK/ERK pathway and its role in overcoming cancer cell drug resistance by sesquiterpene lactones. The MAPK/ERK pathway is a critical signaling cascade involving three classes of kinases: MAPKKK, MAPKK, and MAPK, which sequentially phosphorylate downstream targets. It begins with the activation of MAPKKKs, which subsequently activate MEK1 and MEK2. These, in turn, lead to the activation of ERK1 and ERK2, the final effectors of the cascade. Alterations in components of the Ras/BRAF/MEK/ERK pathway can result in the sustained activation of downstream signaling. This continuous activation promotes the expression of genes involved in cell survival and proliferation, enhances anti-apoptotic signaling, and ultimately contributes to chemotherapy resistance. Furthermore, the MAPK/ERK pathway interacts with the TRAIL pathway, working together to regulate drug resistance. MAPK: Mitogen-activated protein kinase; ERK: extracellular signal-regulated kinase; MAPKKK: MAPK kinase kinase; MAPKK/MEK: MAPK kinase; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand.

RAF), activate the MAPKKs MEK1 and MEK2, which, in turn, activate the final effectors, ERK1 and ERK2^[161]. ERK1/2 are central to translating extracellular signals into intracellular responses, and four major MAPK cascades have been identified: ERK1/2, c-Jun N-terminal kinase (JNK), p38 MAPK, and ERK5^[161]. ERK1/2 activation occurs through phosphorylation by MEK1/2, which are activated by serine/threonine kinases from the Raf family^[162]. Once phosphorylated, ERK1/2 modulate transcription factors, such as ELK1, ETS, FOS, JUN, MYC, and SP1, to regulate gene expression related to cellular proliferation and cell cycle control^[163]. Additionally, ERK1/2 phosphorylate intracellular kinases, including RAKs, MNKs, and MSKs, which contribute to cellular growth and attachment^[164]. Under normal physiological conditions, the MAPK/ERK pathway plays a tumor-suppressive role by promoting cellular senescence and facilitating protein degradation, both essential for cell cycle progression and survival^[165]. However, dysregulation of this pathway, often driven by abnormal activation of RTKs and their downstream effectors, such as RAS, PI3K, and SRC, leads to its upregulation, thereby driving cancer progression and drug resistance.

The MAPK/ERK pathway's pivotal role in cancer initiation, progression, and resistance makes it a key target for therapeutic intervention. In many cancers, excessive activation of this pathway, driven by molecules like Ras, B-Raf, and MEK, promotes cell proliferation and survival, contributing to drug resistance^[166-168]. Sesquiterpene lactones have emerged as potential inhibitors of this pathway, reducing the activity of key molecules within the cascade and suppressing both cancer cell proliferation and resistance. For instance, osimertinib, which is effective in treating NSCLC, faces limitations due to acquired resistance. Costunolide has been shown to directly inhibit MEK1/2, thereby blocking MAPK/ERK signaling and reversing tumor cell resistance to osimertinib^[169]. Similarly, vemurafenib, a BRAF (V600E)-specific inhibitor for melanoma, encounters resistance, which can be overcome by combining it with DETD-35. This combination suppresses MEK expression, inhibits MAPK/ERK signaling, and counteracts vemurafenib resistance^[52].

Phosphorylation of ERK1/2 is a critical event in the activation of the MAPK/ERK pathway. Abnormal activation of ERK1/2 accelerates tumor progression and induces drug resistance^[170]. In this context, sesquiterpene lactones inhibit ERK1/2 phosphorylation, disrupt downstream signaling, and reduce resistance to chemotherapy. As a result, combination therapies targeting ERK1/2-related resistance have gained increasing attention in research. In ovarian cancer, artesunate and methotrexate conjugates inhibit ERK1/2 phosphorylation, suppress MAPK/ERK signaling, and enhance drug sensitivity^[171]. In HCC, continuous ERK1/2 activation during cisplatin treatment promotes cell survival and inhibits cisplatin-induced apoptosis, contributing to resistance. However, the combination of dihydroartemisinin with cisplatin reduces p-ERK/ERK expression and reverses cisplatin resistance^[172].

In addition to its role in chemotherapy resistance, aberrant MAPK/ERK activation is a significant factor in TRAIL resistance. Many tumor cells fail to undergo apoptosis following TRAIL treatment due to persistent MAPK/ERK activation^[173]. Modulating MAPK/ERK activity has been shown to enhance TRAIL-induced apoptosis, thus overcoming resistance. Sesquiterpene lactones have emerged as effective TRAIL sensitizers, potentiating TRAIL's anticancer effects in resistant tumors. For example, artesunate reduces MAPK/ERK overactivation and decreases anti-apoptotic factors, such as Bcl-2, thus enhancing TRAIL-induced apoptosis and reversing TRAIL resistance in human cervical cancer cells^[125]. These findings highlight the potential of sesquiterpene lactones in overcoming MAPK/ERK pathway-mediated chemotherapy resistance and warrant further investigation.

STAT3 pathway

The STAT3 signaling pathway plays a pivotal role in regulating various aspects of cancer cell biology, including proliferation, survival, invasion, and immunosuppression, making it a critical target for anticancer strategies^[174,175]. As shown in [Figure 11](#), the STAT3 pathway is activated by cytokines such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and interleukin-6 (IL-6), which bind to their respective receptors^[176,177]. This binding activates Janus kinases (JAKs), which, in turn, phosphorylate tyrosine residues on STAT3, specifically Tyr705. The phosphorylated STAT3 then binds to these phosphotyrosines through its Src Homology 2 (SH2) domain, promoting STAT3 dimerization. These dimers translocate to the nucleus, where they bind to specific DNA response elements, initiating the transcription of genes that regulate cell growth and survival^[178,179].

In addition to the classical pathway, a non-classical STAT3 pathway has been identified, characterized by the phosphorylation of serine 727. This alternative activation occurs via serine/threonine kinases such as JNK1/2, MAPKs, and CDK5, and it is increasingly recognized for its role in cancer biology^[180]. Furthermore, the subcellular localization of STAT3 plays a crucial role in regulating autophagy. Nuclear STAT3 suppresses autophagy by upregulating negative regulators like BCL2, BCL2L1, and MCL1, whereas




Figure 11. An overview of the STAT3 pathway and its role in drug resistance modulation by sesquiterpene lactones. The STAT3 pathway is activated when cytokines, such as EGF and FGF, bind to their respective receptors. This binding activates JAKs, which then phosphorylate STAT3 at tyrosine residue Tyr705, leading to its activation. Upon activation, STAT3 dimerizes and translocates to the nucleus, where it regulates gene expression. The activation of STAT3 is associated with chemotherapy resistance, as it upregulates downstream factors involved in apoptosis inhibition and DNA repair. Moreover, the STAT3 pathway interacts with the TRAIL pathway, which contributes to the ability of sesquiterpene lactones to overcome drug resistance in cancer cells. STAT3: Signal transducer and activator of the transcription 3; EGF: epidermal growth factor; FGF: fibroblast growth factor; JAKs: Janus kinases; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand.

cytoplasmic STAT3 inhibits autophagy by interacting with proteins such as EIF2AK2 and FOXO^[181,182].

Given its central role in tumorigenesis and resistance to therapy, STAT3 represents an important target for therapeutic intervention. Specifically, sesquiterpene lactones have shown promising potential in overcoming chemotherapy resistance by modulating the STAT3 pathway^[183]. These compounds inhibit STAT3 signaling by either blocking its phosphorylation or targeting upstream JAK kinases, thereby preventing STAT3 activation and enhancing the effectiveness of chemotherapeutic agents^[184]. For example, in doxorubicin-resistant breast cancer cells, upregulated STAT3 activation correlates with drug resistance. Alantolactone, a sesquiterpene lactone, significantly reduces STAT3 phosphorylation, enhancing the anti-proliferative effects of doxorubicin and overcoming resistance^[185]. Similarly, in acute myeloid leukemia (AML), aberrant JAK/STAT3 activation contributes to drug resistance. Artesunate inhibits JAK/STAT3 signaling, reversing resistance to cytarabine and demonstrating the potential of sesquiterpene lactones in AML treatment^[186].

In addition to its role in drug resistance, STAT3 promotes cancer cell survival by upregulating anti-apoptotic proteins such as Bcl-2 and Bcl-xL, which help cancer cells evade chemotherapy-induced

apoptosis^[187]. Sesquiterpene lactones inhibit STAT3 activation, leading to reduced expression of these anti-apoptotic factors and enhancing tumor cell sensitivity to chemotherapy. For instance, in GC, parthenolide reverses cisplatin resistance by modulating STAT3 signaling and downregulating anti-apoptotic proteins^[66].

Moreover, STAT3 is critical for DNA repair mechanisms following chemotherapy-induced DNA damage. By enhancing the expression of DNA repair proteins, STAT3 contributes to cancer cell survival and resistance to treatment^[188]. Sesquiterpene lactones, by inhibiting STAT3, impair DNA repair mechanisms, sensitizing cancer cells to chemotherapy. A notable example is dihydroartemisinin, which targets the STAT3/DDA1 pathway in breast cancer, inhibiting DDA1 expression and enhancing cisplatin efficacy^[189].

Persistent activation of STAT3 also contributes to resistance to TRAIL therapy by upregulating anti-apoptotic proteins and downregulating death receptor expression^[190]. In this context, sesquiterpene lactones sensitize tumor cells to TRAIL-induced apoptosis by inhibiting STAT3. For instance, parthenolide enhances TRAIL sensitivity in HCC by inducing the expression of death receptors TRAIL-R1 and TRAIL-R2. Combining parthenolide with TRAIL significantly augments its anticancer effects and overcomes resistance^[191]. These findings underscore the potential of sesquiterpene lactones in overcoming cancer resistance through STAT3 pathway modulation, making them promising candidates for further therapeutic development.

DISCUSSION

In this review, we systematically analyze the chemical properties of 30 natural sesquiterpene lactones and their recent advances in anticancer and anti-drug resistance effects, focusing particularly on elucidating their mechanisms of action through five key signaling pathways. Despite the promising anticancer potential of sesquiterpene lactones, their clinical applications face several significant challenges, including low water solubility, poor stability, high toxicity, and insufficient bioavailability. These issues hinder their broader use in clinical settings. However, structural derivatization has emerged as a promising strategy to overcome these limitations. Modifying the molecular structure of sesquiterpene lactones, such as parthenolide and micheliolide, by introducing functional groups enhances their specificity for cancer cell targets, thus improving anticancer efficacy^[192]. Additionally, synthesizing dimers or polymers, such as xanthipungolide, through a biomimetic tandem reaction using xanthatin as a precursor, has been shown to enhance both stability and biological activity^[193]. Furthermore, combining sesquiterpene lactone derivatives with targeted delivery vectors, such as nanoparticles or antibodies, holds significant promise for improving specificity and minimizing toxicity to normal cells^[194]. These advancements address the inherent limitations of sesquiterpene lactones and pave the way for their broader integration into clinical practice.

Expanding the scope of research, recent studies have increasingly emphasized the impact of sesquiterpene lactones on cancer stem cells (CSCs) and the immune system, further enhancing their anticancer potential. CSCs are characterized by self-renewal and differentiation capabilities, which contribute to cancer progression, recurrence, metastasis, and drug resistance^[195]. These properties make CSCs a critical target for anticancer therapies, and sesquiterpene lactones offer a unique opportunity to inhibit their role in cancer progression. For example, parthenolide has been shown to suppress CSCs self-renewal and differentiation^[196], while costunolide and parthenolide induce apoptosis in CSCs by elevating intracellular ROS levels^[197,198]. Additionally, artemisinin and gaillardin inhibit CSCs migration and invasion, thereby reducing metastasis.

Beyond their effects on CSCs, sesquiterpene lactones show promise in enhancing the effectiveness of immunotherapy, particularly immune checkpoint inhibitors. Despite the success of immunotherapy in

cancer treatment, CSCs often contribute to therapy resistance^[199]. In this context, sesquiterpene lactones, such as parthenolide, have demonstrated the ability to enhance immunotherapy efficacy. Parthenolide inhibits the NF- κ B signaling pathway, reduces pro-inflammatory cytokine secretion, and mitigates the immunosuppressive tumor microenvironment^[200]. Moreover, compounds like britanin and artesunate have been shown to downregulate the immune escape molecule PD-L1 in CSCs, facilitating the effectiveness of immune checkpoint inhibitors^[86,201].

Another promising strategy for maximizing the therapeutic potential of sesquiterpene lactones is combination therapy. Combining these compounds with existing anticancer drugs has attracted significant attention due to its ability to optimize therapeutic efficacy, overcome drug resistance, and improve patient outcomes^[202]. Recent studies have revealed significant synergistic effects between sesquiterpene lactones and other chemotherapeutic agents, leading to enhanced anticancer efficacy, reduced resistance, and diminished chemotherapy-related side effects^[203,204]. This combinational approach not only refines therapeutic regimens but also provides a robust foundation for developing safer and more effective anticancer strategies.

CONCLUSION

This review provides a comprehensive analysis of the anticancer and anti-drug resistance properties of sesquiterpene lactones. By focusing on five key signaling pathways, we have elucidated their underlying mechanisms and therapeutic potential. Additionally, we have discussed their roles in targeting CSCs, enhancing immunotherapy, and synergizing with existing drugs to overcome drug resistance. These findings offer valuable insights into the future development of sesquiterpene lactones as innovative cancer treatments. However, for these compounds to realize their full clinical potential, future research must address challenges such as optimizing bioavailability, reducing toxicity, and developing targeted delivery systems. Continued exploration in these areas is essential for improving cancer therapy outcomes and facilitating the clinical translation of these promising compounds.

DECLARATIONS

Authors' contributions

Conceptualization: Chen GQ, Chen S, Chen JW

Data curation and original draft preparation: Teng C, Chen JW, Chen GQ, Chen S

Figures and Tables: Teng C, Chen JW, Shen LS

Review and editing: Chen GQ, Chen S, Chen JW

All authors contributed to the article and approved the submitted version.

Availability of data and materials

Not applicable.

Financial support and sponsorship

This research was funded by Shenzhen Science and Technology Innovation Commission (JCYJ20220531090802006), Innovation and Technology Fund-Mainland-Hong Kong Joint Funding Scheme (MHP/010/20).

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2025.

REFERENCES

1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer.* 2019;144:1941-53. DOI
2. Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. *CA Cancer J Clin.* 2022;72:409-36. DOI
3. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. *Chem Rev.* 2009;109:3012-43. DOI PubMed
4. Naeem A, Hu P, Yang M, et al. Natural products as anticancer agents: current status and future perspectives. *Molecules.* 2022;27:8367. DOI PubMed PMC
5. Seaman FC. Sesquiterpene lactones as taxonomic characters in the asteraceae. *Bot Rev.* 1982;48:121-594. DOI
6. Schmidt TJ. Structure-activity relationships of sesquiterpene lactones. *Stud Nat Prod Chem.* 2006;33:309-92. DOI
7. Babaei G, Aliarab A, Abroon S, Rasmi Y, Aziz SG. Application of sesquiterpene lactone: a new promising way for cancer therapy based on anticancer activity. *Biomed Pharmacother.* 2018;106:239-46. DOI PubMed
8. Krishna S, Ganapathi S, Ster IC, et al. A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. *EBioMedicine.* 2015;2:82-90. DOI PubMed PMC
9. Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. *Invest New Drugs.* 2004;22:299-305. DOI
10. Efferth T. From ancient herb to modern drug: artemisia annua and artemisinin for cancer therapy. *Semin Cancer Biol.* 2017;46:65-83. DOI PubMed
11. Liu Y, Zhang X, Cheng F, et al. Xanthatin induce DDP-resistance lung cancer cells apoptosis through regulation of GLUT1 mediated ROS accumulation. *Drug Dev Res.* 2023;84:1266-78. DOI PubMed
12. Chen J, Chen B, Zou Z, et al. Costunolide enhances doxorubicin-induced apoptosis in prostate cancer cells via activated mitogen-activated protein kinases and generation of reactive oxygen species. *Oncotarget.* 2017;8:107701-15. DOI PubMed PMC
13. Xu Z, Xu J, Sun S, et al. Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma. *Redox Biol.* 2022;54:102351. DOI PubMed PMC
14. Chun J, Park SM, Lee M, Ha IJ, Jeong MK. The sesquiterpene lactone-rich fraction of *Inula helenium* L. enhances the antitumor effect of anti-PD-1 antibody in colorectal cancer: integrative phytochemical, transcriptomic, and experimental analyses. *Cancers.* 2023;15:653. DOI PubMed PMC
15. Mangalpady SS, Peña-Corona SI, Borbolla-Jiménez F, et al. Arnicolide D: a multi-targeted anticancer sesquiterpene lactone-preclinical efficacy and mechanistic insights. *Naunyn Schmiedebergs Arch Pharmacol.* 2024;397:6317-36. DOI PubMed
16. Liu X, Wang X. Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents. *Chin J Nat Med.* 2022;20:814-29. DOI
17. Gao Y, Nie Z, Cao H, et al. Scabertopin derived from *Elephantopus Scaber* L. mediates necroptosis by inducing reactive oxygen species production in bladder cancer in vitro. *Cancers.* 2022;14:5976. DOI PubMed PMC
18. Tu Y. Artemisinin-A gift from traditional Chinese medicine to the world (Nobel Lecture). *Angew Chem Int Ed Engl.* 2016;55:10210-26. DOI PubMed
19. Balint GA. Artemisinin and its derivatives: an important new class of antimalarial agents. *Pharmacol Ther.* 2001;90:261-5. DOI PubMed
20. Liu C. Discovery and development of artemisinin and related compounds. *Chin Herb Med.* 2017;9:101-14. DOI
21. Tiwari MK, Chaudhary S. Artemisinin-derived antimalarial endoperoxides from bench-side to bed-side: chronological advancements and future challenges. *Med Res Rev.* 2020;40:1220-75. DOI PubMed
22. Li Y. Qinghaosu (artemisinin): chemistry and pharmacology. *Acta Pharmacol Sin.* 2012;33:1141-6. DOI PubMed PMC
23. Zeng ZW, Chen D, Chen L, He B, Li Y. A comprehensive overview of Artemisinin and its derivatives as anticancer agents. *Eur J Med Chem.* 2023;247:115000. DOI
24. Jia J, Qin Y, Zhang L, et al. Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis. *Mol Med Rep.* 2016;13:4461-8. DOI
25. Li B, Bu S, Sun J, Guo Y, Lai D. Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. *Acta Biochim Biophys Sin.* 2018;50:1227-35. DOI
26. Wang D, Zhong B, Li Y, Liu X. Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling. *Oncol Lett.* 2018;15:1949-54. DOI PubMed PMC
27. Cui YQ, Liu YJ, Zhang F. The suppressive effects of Britannin (Bri) on human liver cancer through inducing apoptosis and autophagy via AMPK activation regulated by ROS. *Biochem Biophys Res Commun.* 2018;497:916-23. DOI PubMed

28. Chen Y, Wang F, Wu P, et al. Artesunate induces apoptosis, autophagy and ferroptosis in diffuse large B cell lymphoma cells by impairing STAT3 signaling. *Cell Signal.* 2021;88:110167. DOI
29. Beccafico S, Morozzi G, Marchetti MC, et al. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. *Carcinogenesis.* 2015;36:1071-83. DOI PubMed
30. Zhou X, Chen Y, Wang F, et al. Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells. *Chem Biol Interact.* 2020;331:109273. DOI
31. Konishi T, Shimada Y, Nagao T, Okabe H, Konoshima T. Antiproliferative sesquiterpene lactones from the roots of *Inula helenium*. *Biol Pharm Bull.* 2002;25:1370-2. DOI PubMed
32. Tepkeeva II, Aushev VN, Zborovskaya IB, Demushkin VP. Cytostatic activity of peptide extracts of medicinal plants on transformed A549, H1299, and HeLa Cells. *Bull Exp Biol Med.* 2009;147:48-51. DOI PubMed
33. O'Shea S, Lucey B, Cotter L. *In vitro* activity of *Inula helenium* against clinical *Staphylococcus aureus* strains including MRSA. *Br J Biomed Sci.* 2009;66:186-9. DOI PubMed
34. Cantrell CL, Abate L, Fronczek FR, Franzblau SG, Quijano L, Fischer NH. Antimycobacterial eudesmanolides from *Inula helenium* and *Rudbeckia subtomentosa*. *Planta Med.* 1999;65:351-5. DOI PubMed
35. Zhao F, Xu H, He EQ, Jiang YT, Liu K. Inhibitory effects of sesquiterpenes from *Saussurea lappa* on the overproduction of nitric oxide and TNF-alpha release in LPS-activated macrophages. *J Asian Nat Prod Res.* 2008;10:1045-53. DOI PubMed
36. Chen J, Zhang Y, Huang R, et al. Alantolactone inhibits oesophageal adenocarcinoma cells through nuclear factor erythroid 2-related factor 2-mediated reactive oxygen species increment. *Basic Clin Pharmacol Toxicol.* 2023;132:253-62. DOI PubMed
37. Ren Y, Lv C, Zhang J, et al. Alantolactone exhibits antiproliferative and apoptosis-promoting properties in colon cancer model via activation of the MAPK-JNK/c-Jun signaling pathway. *Mol Cell Biochem.* 2021;476:4387-403. DOI
38. Yin C, Dai X, Huang X, et al. Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model. *J Cell Mol Med.* 2019;23:2194-206. DOI PubMed PMC
39. Kim MY, Lee H, Ji SY, et al. Induction of apoptosis by isoalantolactone in human hepatocellular carcinoma Hep3B cells through activation of the ROS-dependent JNK signaling pathway. *Pharmaceutics.* 2021;13:1627. DOI PubMed PMC
40. Li J, Zhu P, Chen Y, et al. Isoalantolactone induces cell cycle arrest, apoptosis and autophagy in colorectal cancer cells. *Front Pharmacol.* 2022;13:903599. DOI PubMed PMC
41. Zhang C, Huang L, Xiong J, et al. Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway. *PLoS One.* 2021;16:e0247752. DOI PubMed PMC
42. Lee SH, Cho YC, Lim JS. Costunolide, a sesquiterpene lactone, suppresses skin cancer via induction of apoptosis and blockage of cell proliferation. *Int J Mol Sci.* 2021;22:2075. DOI PubMed PMC
43. Xu C, Huang X, Lei X, et al. Costunolide-induced apoptosis via promoting the reactive oxygen species and inhibiting AKT/GSK3 β pathway and activating autophagy in gastric cancer. *Front Cell Dev Biol.* 2021;9:722734. DOI PubMed PMC
44. Zhuge W, Chen R, Vladimir K, et al. Costunolide specifically binds and inhibits thioredoxin reductase 1 to induce apoptosis in colon cancer. *Cancer Lett.* 2018;412:46-58. DOI
45. Peng Y, Zhou T, Wang S, Bahetjan Y, Li X, Yang X. Dehydrocostus lactone inhibits the proliferation of esophageal cancer cells in vivo and in vitro through ROS-mediated apoptosis and autophagy. *Food Chem Toxicol.* 2022;170:113453. DOI
46. Lee KH, Cowherd CM, Wolo MT. Antitumor agents. XV: deoxyelephantopin, an antitumor principle from *Elephantopus carolinianus* Willd. *J Pharm Sci.* 1975;64:1572-3. DOI PubMed
47. Mehmood T, Muanprasat C. Deoxyelephantopin and its isomer isodeoxyelephantopin: anti-cancer natural products with multiple modes of action. *Molecules.* 2022;27:2086. DOI PubMed PMC
48. Bai M, Chen JJ, Xu W, et al. Elephantopinolide A-P, germacrane-type sesquiterpene lactones from *Elephantopus scaber* induce apoptosis, autophagy and G2/M phase arrest in hepatocellular carcinoma cells. *Eur J Med Chem.* 2020;198:112362. DOI
49. Kabeer FA, Rajalekshmi DS, Nair MS, Prathapan R. Molecular mechanisms of anticancer activity of deoxyelephantopin in cancer cells. *Integr Med Res.* 2017;6:190-206. DOI PubMed PMC
50. Hong L, Chen J, Wu F, et al. Isodeoxyelephantopin inactivates thioredoxin reductase 1 and activates ROS-mediated JNK signaling pathway to exacerbate cisplatin effectiveness in human colon cancer cells. *Front Cell Dev Biol.* 2020;8:580517. DOI PubMed PMC
51. Verma SS, Rai V, Awasthee N, et al. Isodeoxyelephantopin, a sesquiterpene lactone induces ROS generation, suppresses NF- κ B activation, modulates lncRNA expression and exhibit activities against breast cancer. *Sci Rep.* 2019;9:17980. DOI PubMed PMC
52. Feng JH, Nakagawa-Goto K, Lee KH, Shyr LF. A novel plant sesquiterpene lactone derivative, DETD-35, suppresses BRAFV600E mutant melanoma growth and overcomes acquired vemurafenib resistance in mice. *Mol Cancer Ther.* 2016;15:1163-76. DOI PubMed PMC
53. Nakagawa-Goto K, Chen JY, Cheng YT, et al. Novel sesquiterpene lactone analogues as potent anti-breast cancer agents. *Mol Oncol.* 2016;10:921-37. DOI PubMed PMC
54. Cvetanova B, Li MY, Yang CC, et al. Sesquiterpene lactone deoxyelephantopin isolated from *Elephantopus scaber* and its derivative DETD-35 suppress BRAF^{V600E} mutant melanoma lung metastasis in mice. *Int J Mol Sci.* 2021;22:3226. DOI PubMed PMC
55. Yan QL, Wang XY, Bai M, Zhang X, Song SJ, Yao GD. Sesquiterpene lactones from *Elephantopus scaber* exhibit cytotoxic effects on glioma cells by targeting GSTP1. *Bioorg Chem.* 2022;129:106183. DOI
56. Wiedhopf RM, Young M, Bianchi E, Cole JR. Tumor inhibitory agent from *Magnolia grandiflora* (Magnoliaceae). I. Parthenolide. *J Pharm Sci.* 1973;62:345. DOI PubMed

57. Ghantous A, Sinjab A, Herczeg Z, Darwiche N. Parthenolide: from plant shoots to cancer roots. *Drug Discov Today.* 2013;18:894-905. DOI PubMed
58. Woods JR, Mo H, Bieberich AA, Alavanja T, Colby DA. Amino-derivatives of the sesquiterpene lactone class of natural products as prodrugs. *Med Chem Commun.* 2013;4:27-33. DOI
59. Dong Y, Qian X, Li J. Sesquiterpene lactones and cancer: new insight into antitumor and anti-inflammatory effects of parthenolide-derived dimethylaminomichelolide and micheliolide. *Comput Math Methods Med.* 2022;2022:3744837. DOI PubMed PMC
60. Jin P, Madieh S, Augsburger LL. The solution and solid state stability and excipient compatibility of parthenolide in feverfew. *AAPS PharmSciTech.* 2007;8:E105. DOI PubMed PMC
61. Peng F, Li H, Li S, et al. Correction: Micheliolide ameliorates renal fibrosis by suppressing the Mtdh/BMP/MAPK pathway. *Lab Invest.* 2020;100:786-7. DOI PubMed PMC
62. Zhu J, Zhao J, Yu Z, et al. Epoxymichelolide, a novelguaiane-type sesquiterpene lactone, inhibits NF- κ B/COX-2 signaling pathways by targeting leucine 281 and leucine 25 in IKK β in renal cell carcinoma. *Int J Oncol.* 2018;53:987-1000. DOI PubMed PMC
63. Jhanwar-Uniyal M, Wainwright JV, Mohan AL, et al. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. *Adv Biol Regul.* 2019;72:51-62. DOI
64. Viennois E, Xiao B, Ayyadurai S, et al. Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer. *Lab Invest.* 2014;94:950-65. DOI
65. Karam L, Abou Staiteieh S, Chaaban R, et al. Anticancer activities of parthenolide in primary effusion lymphoma preclinical models. *Mol Carcinog.* 2021;60:567-81. DOI
66. Li H, Lu H, Lv M, Wang Q, Sun Y. Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway. *Oncol Lett.* 2018;15:3572-9. DOI PubMed PMC
67. Sun L, Yuan W, Wen G, et al. Parthenolide inhibits human lung cancer cell growth by modulating the IGF-1R/PI3K/Akt signaling pathway. *Oncol Rep.* 2020;44:1184-93. DOI
68. Duan D, Zhang J, Yao J, Liu Y, Fang J. Targeting thioredoxin reductase by parthenolide contributes to inducing apoptosis of HeLa cells. *J Biol Chem.* 2016;291:10021-31. DOI PubMed PMC
69. Liu W, Wang X, Sun J, Yang Y, Li W, Song J. Parthenolide suppresses pancreatic cell growth by autophagy-mediated apoptosis. *Onco Targets Ther.* 2017;10:453-61. DOI PubMed PMC
70. Tang X, Ding Q, Chen C, et al. Micheliolide inhibits gastric cancer growth *in vitro* and *in vivo* via blockade of the IL-6/STAT3 pathway. *Pharmazie.* 2019;74:175-8. DOI PubMed
71. Feng D, Liu M, Liu Y, et al. Micheliolide suppresses the viability, migration and invasion of U251MG cells via the NF- κ B signaling pathway. *Oncol Lett.* 2020;20:67. DOI PubMed PMC
72. Zhang S, Hua Z, Ba G, et al. Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL. *Cancer Cell Int.* 2021;21:619. DOI PubMed PMC
73. Yao S, Ye J, Yin M, Yu R. DMAMCL exerts antitumor effects on hepatocellular carcinoma both *in vitro* and *in vivo*. *Cancer Lett.* 2020;483:87-97. DOI
74. Wang Y, Zhang J, Yang Y, et al. ROS generation and autophagosome accumulation contribute to the DMAMCL-induced inhibition of glioma cell proliferation by regulating the ROS/MAPK signaling pathway and suppressing the Akt/mTOR signaling pathway. *Onco Targets Ther.* 2019;12:1867-80. DOI PubMed PMC
75. Johansson MH. Reversible Michael additions: covalent inhibitors and prodrugs. *Mini Rev Med Chem.* 2012;12:1330-44. DOI PubMed
76. Liu YQ, Zhou GB. Promising anticancer activities and mechanisms of action of active compounds from the medicinal herb *Centipeda minima* (L.) A. Braun & Asch. *Phytomedicine.* 2022;106:154397. DOI PubMed
77. Liu R, Dow Chan B, Mok DK, Lee CS, Tai WC, Chen S. Arnicolide D, from the herb *Centipeda minima*, is a therapeutic candidate against nasopharyngeal carcinoma. *Molecules.* 2019;24:1908. DOI PubMed PMC
78. Qu Z, Lin Y, Mok DK, Bian Q, Tai WC, Chen S. Arnicolide D inhibits triple negative breast cancer cell proliferation by suppression of Akt/mTOR and STAT3 signaling pathways. *Int J Med Sci.* 2020;17:1482-90. DOI PubMed PMC
79. Zhu P, Zheng Z, Fu X, et al. Arnicolide D exerts anti-melanoma effects and inhibits the NF- κ B pathway. *Phytomedicine.* 2019;64:153065. DOI
80. Lin YS, Sun Z, Shen LS, et al. Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells. *Cell Death Discov.* 2024;10:134. DOI PubMed PMC
81. Tan Z, Li X, Chen X, et al. Ellagic acid inhibits tumor growth and potentiates the therapeutic efficacy of sorafenib in hepatocellular carcinoma. *Heliyon.* 2024;10:e23931. DOI PubMed PMC
82. Su T, Wang YP, Wang XN, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of brevilin A. *Life Sci.* 2020;241:117169. DOI
83. Liu R, Qu Z, Lin Y, Lee CS, Tai WC, Chen S. Brevilin A induces cell cycle arrest and apoptosis in nasopharyngeal carcinoma. *Front Pharmacol.* 2019;10:594. DOI PubMed PMC
84. Saleem MZ, Nisar MA, Alshwmi M, et al. Brevilin A inhibits STAT3 signaling and induces ROS-dependent apoptosis, mitochondrial stress and endoplasmic reticulum stress in MCF-7 breast cancer cells. *Onco Targets Ther.* 2020;13:435-50. DOI PubMed PMC
85. You P, Wu H, Deng M, Peng J, Li F, Yang Y. Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via

- mitochondrial pathway and PI3K/AKT/mTOR inactivation. *Biomed Pharmacother.* 2018;98:619-25. DOI
86. Bailly C. Anticancer targets and signaling pathways activated by britannin and related pseudoguaianolide sesquiterpene lactones. *Biomedicines.* 2021;9:1325. DOI PubMed PMC
 87. Seca AM, Grigore A, Pinto DC, Silva AM. The genus *Inula* and their metabolites: from ethnopharmacological to medicinal uses. *J Ethnopharmacol.* 2014;154:286-310. DOI PubMed
 88. Zhang YF, Zhang ZH, Li MY, et al. Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1 α in cancer. *Phytomedicine.* 2021;81:153425. DOI
 89. Deng M, Chen H, Long J, Song J, Xie L, Li X. Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics. *Arch Pharm Res.* 2021;44:633-54. DOI
 90. Wang K, Huang W, Sang X, et al. Atractylenolide I inhibits colorectal cancer cell proliferation by affecting metabolism and stemness via AKT/mTOR signaling. *Phytomedicine.* 2020;68:153191. DOI
 91. Wang J, Nasser MI, Adlat S, Ming Jiang M, Jiang N, Gao L. Atractylenolide II induces apoptosis of prostate cancer cells through regulation of AR and JAK2/STAT3 signaling pathways. *Molecules.* 2018;23:3298. DOI PubMed PMC
 92. Cho IJ, Kim JK, Kim EO, et al. Hemisteptin A induces apoptosis of hepatocellular carcinoma cells by downregulating STAT3. *Int J Mol Sci.* 2021;22:4743. DOI PubMed PMC
 93. Kim KY, Yun UJ, Yeom SH, et al. Inhibition of autophagy promotes hemisteptin A-induced apoptosis via reactive oxygen species-mediated AMPK-dependent signaling in human prostate cancer cells. *Biomolecules.* 2021;11:1806. DOI PubMed PMC
 94. Wang L, Wang J, Li F, et al. Cytotoxic sesquiterpene lactones from aerial parts of *Xanthium sibiricum*. *Planta Med.* 2013;79:661-5. DOI
 95. Chen H, Zhu T, Huang X, et al. Xanthatin suppresses proliferation and tumorigenicity of glioma cells through autophagy inhibition via activation of the PI3K-Akt-mTOR pathway. *Pharmacol Res Perspect.* 2023;11:e01041. DOI PubMed PMC
 96. Shi TL, Zhang L, Cheng QY, et al. Xanthatin induces apoptosis by activating endoplasmic reticulum stress in hepatoma cells. *Eur J Pharmacol.* 2019;843:1-11. DOI
 97. Miranda MA, Varela RM, Torres A, Molinillo JM, Gualtieri SC, Macías FA. Phytotoxins from *Tithonia diversifolia*. *J Nat Prod.* 2015;78:1083-92. DOI PubMed
 98. Wei R, Zhao Y, Wang J, et al. Tagitinin C induces ferroptosis through PERK-Nrf2-HO-1 signaling pathway in colorectal cancer cells. *Int J Biol Sci.* 2021;17:2703-17. DOI PubMed PMC
 99. Andersen TB, López CQ, Manczak T, Martinez K, Simonsen HT. Thapsigargin - from *Thapsia* L. to mipsagargin. *Molecules.* 2015;20:6113-27. DOI PubMed PMC
 100. Huang F, Wang P, Wang X. Thapsigargin induces apoptosis of prostate cancer through cofilin-1 and paxillin. *Oncol Lett.* 2018;16:1975-80. DOI PubMed PMC
 101. Wu L, Huang X, Kuang Y, Xing Z, Deng X, Luo Z. Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study. *Drug Des Devel Ther.* 2019;13:2787-98. DOI PubMed PMC
 102. Chen JH, Wu ATH, Tzeng DTW, Huang CC, Tzeng YM, Chao TY. Antrocin, a bioactive component from *Antrodia cinnamomea*, suppresses breast carcinogenesis and stemness via downregulation of β -catenin/Notch1/Akt signaling. *Phytomedicine.* 2019;52:70-8. DOI PubMed
 103. Chiu KY, Wu CC, Chia CH, Hsu SL, Tzeng YM. Inhibition of growth, migration and invasion of human bladder cancer cells by antrocin, a sesquiterpene lactone isolated from *Antrodia cinnamomea*, and its molecular mechanisms. *Cancer Lett.* 2016;373:174-84. DOI PubMed
 104. Roozbehani M, Abdolmohammadi MH, Hamzeloo-Moghadam M, Irani S, Fallahian F. Gaillardin, a potent sesquiterpene lactone induces apoptosis via down-regulation of NF- κ B in gastric cancer cells, AGS and MKN45. *J Ethnopharmacol.* 2021;281:114529. DOI PubMed
 105. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nat Rev Cancer.* 2009;9:550-62. DOI PubMed
 106. Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. *Front Pharmacol.* 2021;12:628690. DOI PubMed PMC
 107. Tian LY, Smit DJ, Jücker M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism. *Int J Mol Sci.* 2023;24:2652. DOI PubMed PMC
 108. Song M, Bode AM, Dong Z, Lee MH. AKT as a therapeutic target for cancer. *Cancer Res.* 2019;79:1019-31. DOI PubMed
 109. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. *Cell Signal.* 2002;14:381-95. DOI
 110. Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. *J Hematol Oncol.* 2019;12:71. DOI PubMed PMC
 111. Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. *Cell Biosci.* 2020;10:31. DOI PubMed PMC
 112. Mafi S, Mansoori B, Taeb S, et al. mTOR-mediated regulation of immune responses in cancer and tumor microenvironment. *Front Immunol.* 2021;12:774103. DOI PubMed PMC
 113. Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. *Cancer Chemother*

- Pharmacol.* 2013;71:829-42. DOI PubMed
114. Murugan AK. mTOR: role in cancer, metastasis and drug resistance. *Semin Cancer Biol.* 2019;59:92-111. DOI
 115. Chen MY, Hsu CH, Setiawan SA, et al. Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis. *Phytomedicine.* 2023;108:154478. DOI
 116. Jing W, Shuo L, Yingru X, et al. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma. *Biochem Biophys Res Commun.* 2019;519:41-5. DOI
 117. Wang Y, Chen Y, Liu L, He D, Li H. Effects of artemisinin combined with 5-fluorouracil on colon cancer cell proliferation, migration, and drug sensitivity via PI3K/AKT signaling. *J Biomater Tissue Eng.* 2020;10:1600-4. DOI
 118. Brotelle T, Bay JO. [PI3K-AKT-mTOR pathway: Description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer]. *Bull Cancer.* 2016;103:18-29. DOI PubMed
 119. Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. *Cell Death Dis.* 2020;11:797. DOI PubMed PMC
 120. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer.* 2002;2:48-58. DOI PubMed
 121. Cai H, Li L, Jiang J, Zhao C, Yang C. Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway. *Phytother Res.* 2019;33:1683-8. DOI
 122. Zhang S, Feng R, Yuan F, et al. The therapeutic effects of dihydroartemisinin on cisplatin-resistant gastric cancer cells. *Curr Pharm Biotechnol.* 2022;23:276-86. DOI PubMed
 123. Xu J, Zhou JY, Wei WZ, Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. *PLoS One.* 2010;5:e10226. DOI PubMed PMC
 124. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. *Cancer Gene Ther.* 2005;12:228-37. DOI
 125. Thanaketaisarn O, Waiwut P, Sakurai H, Saiki I. Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF- κ B and PI3K/Akt signaling pathways. *Int J Oncol.* 2011;39:279-85. DOI
 126. Hayden MS, Ghosh S. NF- κ B in immunobiology. *Cell Res.* 2011;21:223-44. DOI PubMed PMC
 127. Erstad DJ, Cusack JC Jr. Targeting the NF- κ B pathway in cancer therapy. *Surg Oncol Clin N Am.* 2013;22:705-46. DOI PubMed
 128. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. *Expert Opin Ther Targets.* 2010;14:45-55. DOI PubMed PMC
 129. Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF- κ B pathway for the therapy of diseases: mechanism and clinical study. *Signal Transduct Target Ther.* 2020;5:209. DOI PubMed PMC
 130. Hoesel B, Schmid JA. The complexity of NF- κ B signaling in inflammation and cancer. *Mol Cancer.* 2013;12:86. DOI PubMed PMC
 131. Li Y, Zhao B, Peng J, et al. Inhibition of NF- κ B signaling unveils novel strategies to overcome drug resistance in cancers. *Drug Resist Updat.* 2024;73:101042. DOI
 132. Wei W, Huang H, Zhao S, et al. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF- κ B inhibition and Bcr/Abl protein deletion. *Apoptosis.* 2013;18:1060-70. DOI PubMed
 133. Fang LJ, Shao XT, Wang S, Lu GH, Xu T, Zhou JY. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis. *Planta Med.* 2010;76:258-64. DOI PubMed
 134. Zhang Z, Duan Q, Zhao H, et al. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF- κ B/STAT3 signaling cascade. *Cancer Lett.* 2016;382:53-63. DOI
 135. Ji D, Zhong X, Huang P, et al. Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity *in vitro* and *in vivo* through targeting the NF- κ B signaling pathway in pancreatic cancer. *Aging.* 2020;12:11116-38. DOI PubMed PMC
 136. Holcomb BK, Yip-Schneider MT, Waters JA, Beane JD, Crooks PA, Schmidt CM. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. *J Gastrointest Surg.* 2012;16:1333-40. DOI
 137. Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. *Curr Cancer Drug Targets.* 2006;6:295-311. DOI PubMed
 138. Li Q, Ma Q, Cheng J, et al. Dihydroartemisinin as a sensitizing agent in cancer therapies. *Onco Targets Ther.* 2021;14:2563-73. DOI PubMed PMC
 139. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF- κ B in development and progression of human cancer. *Virchows Arch.* 2005;446:475-82. DOI PubMed
 140. Khongthong P, Roseweir AK, Edwards J. The NF-KB pathway and endocrine therapy resistance in breast cancer. *Endocr Relat Cancer.* 2019;26:R369-80. DOI PubMed
 141. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. *Nat Rev Cancer.* 2010;10:561-74. DOI PubMed
 142. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. *Dev Cell.* 2009;17:9-26. DOI PubMed PMC
 143. Clevers H. Wnt/beta-catenin signaling in development and disease. *Cell.* 2006;127:469-80. DOI PubMed

144. Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt/ β -catenin pathway in ovarian cancer: a review. *Gynecol Oncol.* 2013;131:772-9. DOI PubMed
145. Kolligs FT, Bommer G, Göke B. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. *Digestion.* 2002;66:131-44. DOI PubMed
146. Zhang Y, Wang X. Targeting the Wnt/ β -catenin signaling pathway in cancer. *J Hematol Oncol.* 2020;13:165. DOI PubMed PMC
147. Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. *Cancer Treat Rev.* 2018;62:50-60. DOI PubMed PMC
148. Lorzadeh S, Kohan L, Ghavami S, Azarpira N. Autophagy and the Wnt signaling pathway: a focus on Wnt/ β -catenin signaling. *Biochim Biophys Acta Mol Cell Res.* 2021;1868:118926. DOI PubMed
149. Rodgers SJ, Ooms LM, Oorschot VMJ, et al. INPP4B promotes PI3K α -dependent late endosome formation and Wnt/ β -catenin signaling in breast cancer. *Nat Commun.* 2021;12:3140. DOI PubMed PMC
150. Perry JM, Tao F, Roy A, et al. Overcoming Wnt- β -catenin dependent anticancer therapy resistance in leukaemia stem cells. *Nat Cell Biol.* 2020;22:689-700. DOI PubMed PMC
151. Spaan I, Raymakers RA, van de Stolpe A, Peperzak V. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. *J Hematol Oncol.* 2018;11:67. DOI PubMed PMC
152. Cai W, Chen G, Luo Q, et al. PMP22 regulates self-renewal and chemoresistance of gastric cancer cells. *Mol Cancer Ther.* 2017;16:1187-98. DOI
153. Ismail M, Yang W, Li Y, et al. Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. *Biomaterials.* 2022;287:121608. DOI
154. Wang T, Wang J, Ren W, Liu ZL, Cheng YF, Zhang XM. Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/ β -catenin signaling pathway. *Thorac Cancer.* 2020;11:2316-24. DOI PubMed PMC
155. Law SM, Zheng JJ. Premise and peril of Wnt signaling activation through GSK-3 β inhibition. *iScience.* 2022;25:104159. DOI PubMed PMC
156. Dai X, Chen W, Qiao Y, et al. Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3 β /TCF7/MMP9 pathway and synergies with capecitabine. *Cancer Lett.* 2024;582:216596. DOI
157. Koni M, Pinnarò V, Brizzi MF. The Wnt signalling pathway: a tailored target in cancer. *Int J Mol Sci.* 2020;21:7697. DOI PubMed PMC
158. Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. *Cancer.* 2014;120:3446-56. DOI PubMed PMC
159. Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. *J Recept Signal Transduct Res.* 2015;35:600-4. DOI PubMed
160. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. *Expert Opin Ther Targets.* 2012;16 Suppl 2:S17-27. DOI PubMed
161. Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. *Exp Ther Med.* 2020;19:1997-2007. DOI PubMed PMC
162. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. *Oncogene.* 2007;26:3291-310. DOI PubMed
163. Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. *Trends Biochem Sci.* 2006;31:268-75. DOI
164. Yang SH, Sharrocks AD, Whitmarsh AJ. MAP kinase signalling cascades and transcriptional regulation. *Gene.* 2013;513:1-13. DOI PubMed
165. Deschênes-Simard X, Gaumont-Leclerc MF, Bourdeau V, et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. *Genes Dev.* 2013;27:900-15. DOI PubMed PMC
166. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. *Expert Opin Ther Targets.* 2012;16:103-19. DOI PubMed PMC
167. Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. *Signal Transduct Target Ther.* 2023;8:455. DOI PubMed PMC
168. Healy FM, Prior IA, MacEwan DJ. The importance of Ras in drug resistance in cancer. *Br J Pharmacol.* 2022;179:2844-67. DOI
169. Tian X, Wang R, Gu T, et al. Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer. *Mol Cancer.* 2022;21:193. DOI PubMed PMC
170. Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. *Int J Mol Sci.* 2020;21:1102. DOI PubMed PMC
171. Li X, Zhou Y, Liu Y, et al. Preclinical efficacy and safety assessment of artemisinin-chemotherapeutic agent conjugates for ovarian cancer. *EBioMedicine.* 2016;14:44-54. DOI PubMed PMC
172. Li S, Dai M, Wang F, et al. PD-1/PD-L1 interaction upregulates YAP1 expression in HepG2 cells through MAPK/ERK pathway. *Nat Prod Commun.* 2023;18:1934578X231210413. DOI
173. Lee DY, Lee MW, Lee HJ, et al. ERK1/2 activation attenuates TRAIL-induced apoptosis through the regulation of mitochondria-dependent pathway. *Toxicol In Vitro.* 2006;20:816-23. DOI

174. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. *Cell*. 1999;98:295-303. DOI
175. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. *Nat Rev Cancer*. 2014;14:736-46. DOI
176. Ma JH, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. *Cell Commun Signal*. 2020;18:33. DOI PubMed PMC
177. Wang HQ, Man QW, Huo FY, et al. STAT3 pathway in cancers: past, present, and future. *MedComm*. 2022;3:e124. DOI PubMed PMC
178. Horvath CM, Wen Z, Darnell JE Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. *Genes Dev*. 1995;9:984-94. DOI PubMed
179. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. *Oncogene*. 2000;19:2468-73. DOI PubMed
180. Courapied S, Sellier H, de Carné Trécesson S, et al. The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. *J Biol Chem*. 2010;285:26765-78. DOI PubMed PMC
181. Fukada T, Hibi M, Yamanaka Y, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. *Immunity*. 1996;5:449-60. DOI
182. You L, Wang Z, Li H, et al. The role of STAT3 in autophagy. *Autophagy*. 2015;11:729-39. DOI PubMed PMC
183. Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. *J Exp Clin Cancer Res*. 2024;43:23. DOI PubMed PMC
184. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer*. 2009;9:798-809. DOI PubMed PMC
185. Chun J, Li RJ, Cheng MS, Kim YS. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. *Cancer Lett*. 2015;357:393-403. DOI
186. Su Q, Huang P, Luo X, Zhang P, Li H, Chen Y. Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling. *Hematology*. 2023;28:2255802. DOI
187. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. *Oncogene*. 2002;21:7611-8. DOI
188. Barry SP, Townsend PA, Knight RA, Scarabelli TM, Latchman DS, Stephanou A. STAT3 modulates the DNA damage response pathway. *Int J Exp Pathol*. 2010;91:506-14. DOI PubMed PMC
189. Zhang J, Li Y, Wang JG, Feng JY, Huang GD, Luo CG. Dihydroartemisinin affects STAT3/DDA1 signaling pathway and reverses breast cancer resistance to cisplatin. *Am J Chin Med*. 2023;51:445-59. DOI
190. Chen KF, Tai WT, Liu TH, et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. *Clin Cancer Res*. 2010;16:5189-99. DOI
191. Carlisi D, D'Anneo A, Angileri L, et al. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. *J Cell Physiol*. 2011;226:1632-41. DOI
192. Zeng B, Cheng Y, Zheng K, et al. Design, synthesis and in vivo anticancer activity of novel parthenolide and micheliolide derivatives as NF- κ B and STAT3 inhibitors. *Bioorg Chem*. 2021;111:104973. DOI
193. Feng J, Lei X, Bao R, et al. Enantioselective and collective total syntheses of xanthanolides. *Angew Chem Int Ed Engl*. 2017;56:16323-7. DOI
194. Zahra M, Abrahamse H, George BP. Green nanotech paradigm for enhancing sesquiterpene lactone therapeutics in cancer. *Biomed Pharmacother*. 2024;173:116426. DOI PubMed
195. Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. *J Cell Physiol*. 2019;234:8381-95. DOI PubMed
196. Nguyen NP, Almeida FS, Chi A, et al. Molecular biology of breast cancer stem cells: potential clinical applications. *Cancer Treat Rev*. 2010;36:485-91. DOI
197. Yang YI, Kim JH, Lee KT, Choi JH. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. *Gynecol Oncol*. 2011;123:588-96. DOI PubMed
198. Carlisi D, Buttitta G, Di Fiore R, et al. Parthenolide and DMAPT exert cytotoxic effects on breast cancer stem-like cells by inducing oxidative stress, mitochondrial dysfunction and necrosis. *Cell Death Dis*. 2016;7:e2194. DOI PubMed PMC
199. Tsuchiya H, Shiota G. Immune evasion by cancer stem cells. *Regen Ther*. 2021;17:20-33. DOI PubMed PMC
200. Cai Z, Gao L, Hu K, Wang QM. Parthenolide enhances the metronomic chemotherapy effect of cyclophosphamide in lung cancer by inhibiting the NF- κ B signaling pathway. *World J Clin Oncol*. 2024;15:895-907. DOI PubMed PMC
201. Cao D, Chen D, Xia JN, et al. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation. *Biomed Pharmacother*. 2022;155:113705. DOI
202. Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. *Proc Natl Acad Sci U S A*. 2008;105:4826-31. DOI PubMed PMC
203. Gong RH, Chen M, Huang C, et al. Synergistic anti-colorectal cancer effects of WNT974 combined with artesunate via cooperative regulation of p21, p27, and AKT. *Pharmacol Res Mod Chin Med*. 2024;12:100498. DOI
204. Gong RH, Yang DJ, Kwan HY, Lyu AP, Chen GQ, Bian ZX. Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells. *Int J Med Sci*. 2022;19:175-85. DOI PubMed PMC